Parathyroid hormone-related protein promotes inflammation in the kidney with an obstructed ureter  by Rámila, D. et al.
Parathyroid hormone-related protein promotes
inflammation in the kidney with an obstructed ureter
D Ra´mila1, JA Ardura1, V Esteban2, A Ortega3, M Ruiz-Ortega2, RJ Bosch3 and P Esbrit1
1Bone and Mineral Metabolism Laboratory, Fundacio´n Jime´nez Dı´az (Capio Group) Madrid, Madrid, Spain; 2Vascular and Renal
Laboratory, Fundacio´n Jime´nez Dı´az (Capio Group) and Universidad Auto´noma de Madrid, Madrid, Spain and 3Laboratory of Renal
Physiology and Experimental Nephrology, Department of Physiology, Alcala´ University, Alcala´ de Henares, Spain
Parathyroid hormone-related protein (PTHrP) promotes
fibrogenesis in the acutely damaged kidney. Considering
the relation between fibrosis and inflammation, we studied
transgenic mice that overexpress PTHrP in the proximal
tubule. When unilateral ureteric obstruction was induced in
these transgenic mice, we found that they had more renal
tubulointerstitial damage, leukocyte influx, and expression
of proinflammatory factors than their control littermates.
Reversal of PTHrP constitutive overexpression in these
transgenic mice or treatment of control mice with the PTHrP
antagonist (7–34) decreased this inflammatory response.
Losartan, which abolished obstruction-induced endogenous
PTHrP upregulation, also decreased the latter response
but less effectively in transgenic mice. The PTHrP fragment
(1–36) induced nuclear factor-jB (NF-jB) activation and
proinflammatory cytokine overexpression in mouse cortical
tubule cells in culture as well as migration of the macrophage
cell line Raw 264.7. All these effects were decreased by PTHrP
(7–34) and NF-jB or extracellular signal-regulated kinase
(ERK) activation inhibitors. Our findings suggest a critical role
of PTHrP in the renal inflammatory process that results from
ureteral obstruction and indicate that ERK-mediated NF-jB
activation seems to be an important mechanism whereby
PTHrP triggers renal inflammation.
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Parathyroid hormone (PTH)-related protein (PTHrP) is
upregulated in various experimental nephropathies.1 PTHrP
overexpression correlates with the development of protein-
uria in both diabetic mice and rats with tubulointerstitial
damage after protein overload.2,3 Moreover, recent studies
indicate that PTHrP might contribute to tubular damage,
renal function deterioration, and fibrosis after nephrotoxic
injury in rodents.4–6
Inflammation plays a key role in progressive renal scarring
and fibrogenesis in various kidney diseases.7–10 Nuclear
factor-kB (NF-kB)-related cytokines appear to have an
important role in renal injury-associated inflammation.11–14
This factor commonly consists of a heterodimer of one
p50 subunit and one p65 subunit—the former being trans-
criptionally repressive—that translocates to the nucleus
upon activation to regulate gene transcription.13,15,16 In fact,
angiotensin (Ang) II receptor antagonists confer renal
protection apparently through inhibition of NF-kB-
dependent proinflammatory pathways.12,17 However, the
putative factors triggering renal inflammation are not fully
understood.
PTHrP displays proinflammatory features in various
pathophysiological settings.18 Recently, an increased inter-
stitial macrophage influx was found to be associated with
PTHrP overexpression in mice with folic acid-induced
nephrotoxicity.6 In this study, we explored whether PTHrP
might be a key cytokine-inducing inflammation in the
injured kidney.19,20 We examined the functional conse-
quences of chronic PTHrP upregulation in mouse kidney
after unilateral ureteral obstruction (UUO), characterized
by an early renal inflammatory response.8,19–21 Furthermore,
we assessed the putative intracellular pathways underlying the
proinflammatory effects of PTHrP on renal tubuloepithelial
cells.
RESULTS
Tubulointerstitial alterations occur associated with PTHrP
upregulation in the obstructed mouse kidney
Endogenous mouse PTHrP mRNA levels increased similarly
in the obstructed kidneys of control and PTHrP-over-
expressing transgenic (PTHrP-TG) mice after UUO over
corresponding levels in sham-operated mice (Figure 1a). By
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using PTHrP antiserum C6, recognizing the conserved 107-
111 epitope in intact PTHrP in mice and humans,3,6,22
PTHrP levels were twofold higher in the unobstructed kidney
of PTHrP-TG mice than in that of control littermates and
likewise increased after UUO (Figure 1b). A single band of
an apparent molecular weight of 18 kDa was detected with
this antiserum, corresponding to the single full-length
PTHrP isoform in mice, as reported previously.3,6 Mean-
while, PTH1 receptor (PTH1R) mRNA and protein levels
remained unchanged within the same time period in these
mice (Figure 1a and b).
Tubular atrophy and interstitial fibrotic areas in the
obstructed kidneys occurred earlier, and the former was
higher throughout the study in PTHrP-TG mice than in
control littermates (Figure 2a). Both sham-operated kidneys
and contralateral kidneys (data not shown) from PTHrP-TG
mice showed no structural alterations and had a similar
scarce number of interstitial leukocytes as in control
littermates (Figure 2a and b). Starting 2 days after obstruc-
tion, a dramatic increase of the latter occurred in both types
of mice, mainly in PTHrP-TG mice (Figure 2b).
PTHrP overexpression in the obstructed mouse kidney is
related to increased proinflammatory factors
Various proinflammatory and chemotactic cytokines and cell
adhesion molecules are involved in the inflammatory
response after UUO.8,14,19,21,23 In the unobstructed kidneys,
we observed a higher (mRNA and/or protein) expression of
monocyte chemoattractant protein (MCP)-1, MCP-1 recep-
tor CCR2 (chemokine (C–C motif) receptor 2), RANTES
(regulated upon activation, normal T-cell expressed, and
secreted), and interleukin (IL)-6 in PTHrP-TG mice than in
control mice (Figure 3). After UUO, there was a stepwise
increase of the three former factors in the obstructed kidneys
of control mice. This increase of MCP-1 protein and
RANTES gene expression was higher in PTHrP-TG mice
throughout the study (Figure 3a–c). Meanwhile, CCR2 gene
expression reached its maximum earlier in the PTHrP-TG
mice than in control littermates following obstruction
(Figure 3a–c). A sustained increase of intercellular adhesion
molecule (ICAM)-1 mRNA levels also occurred in the
obstructed kidneys of the former animals (Figure 3d).
In contrast, an early and transient increase of IL-6 gene
expression was observed in these kidneys, which was
more dramatic in PTHrP-TG mice (Figure 3e). Moreover,
consistent with these findings and previous data,14,19 we
found elevated levels of NF-kB activity in the obstructed
mouse kidney extracts, which were significantly higher in
PTHrP-TG mice (Figure 4).
Effects of pharmacological suppression of PTHrP on
inflammation in the obstructed mouse kidney
To confirm that PTHrP was responsible for the proinflam-
matory changes in the obstructed mouse kidney, we used
several experimental maneuvers. First, PTHrP-TG mice
were administered doxycycline (20 mg l1 in drinking water;
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Figure 1 | PTHrP and PTH1R expression in the obstructed kidney from PTHrP-TG mice and their control littermates. In the kidney
of sham-operated mice or the obstructed kidney for 2–6 days, we analyzed endogenous mouse (m)PTHrP gene expression (by real-time
PCR) (a); PTHrP protein (by western blot, using antibody C6 recognizing both endogenous PTHrP and the human PTHrP transgene) (b); and
the PTH1R gene (by real-time PCR) and protein (by western blot) expression (a, b). Representative autoradiograms are also shown in
(b). Experimental values are mean±s.e.m. of 4–6 mice per group at each time period. All values were normalized against corresponding sham
control. *Po0.01 vs corresponding value in control mice; aPo0.01 vs corresponding value in sham-operated mice. AU, arbitrary units.
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a lower dose than that exhibiting anti-inflammatory
effects24,25) for 1 week before and during obstruction
(4 days) to reverse constitutive PTHrP overexpression.6,26
As expected, we did not find any effect of this treatment on
the number of interstitial macrophages (by F4/80 staining) in
the obstructed kidney of control mice; these values were
160±6 or 166±18, with or without doxycycline treatment
(n¼ 4). In contrast, in the obstructed kidneys of PTHrP-TG
mice, doxycycline administration decreased NF-kB activity
(Figure 4), as well as CCR2, RANTES, and ICAM mRNA
levels, to that found in control mice (Figure 5). This indicates
that the higher expression of these factors in PTHrP-TG mice
is accounted for by the PTHrP transgene.
Next, we treated control mice with PTHrP (7–34), a
PTH1R antagonist, before and after UUO.6,27 This treatment
was associated with a significant decrease (about 40–50%) in
interstitial leukocytes and MCP-1 and RANTES expression in
the obstructed kidneys (Figure 6a and b). The AT1 receptor
antagonist losartan was previously shown to abolish PTHrP
upregulation elicited by nephrotoxic acute renal injury in
rats.5 This antagonist, in contrast to an AT2 antagonist, also
prevented the PTHrP mRNA overexpression and decreased
in part the renal inflammatory response in the obstructed
kidneys of control mice (Figure 7a–c). Of note, losartan was
more efficient in this regard in the latter mice than in PTHrP-
TG mice, in which it only inhibited by 25% interstitial
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Figure 2 | Evolution of renal lesions, as well as inflammatory cell infiltration, up to 6 days in the obstructed kidney of control and
PTHrP-TG mice. Renal lesions (assessed by Masson’s staining, original magnification  100) (a), the number of renal interstitial macrophages
(determined by F4/80 staining) (b), and T lymphocytes (identified by CD3 positivity) (c) (original magnification  200) in the kidney of
representative control and PTHrP-TG mice at the indicated days of obstruction or sham operation are shown. Score values are mean±s.e.m.
of 4–6 animals per group at each time. These values corresponding to sham-operated and contralateral kidneys were unchanged throughout
the period of study, and thus those for the different times in each group were pooled. *Po0.01 vs corresponding value in control mice.
aPo0.01 vs corresponding value in sham-operated mice. ND, not detected.
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macrophage infiltration (compared to 60% in control mice),
and it did not significantly affect renal MCP-1 expression
(Figure 7b and c).
Role of NF-jB and ERK activation on the PTHrP-induced
proinflammatory mechanisms in mouse cortical
tubuloepithelial (MCT) cells
Tubular cells produce proinflammatory factors to promote
leukocyte influx after renal scarring.8 Thus, the next
experiments were performed using these cells in vitro to
assess the molecular mechanisms whereby PTHrP induces
inflammation in the obstructed mouse kidney. Consistent
with our in vivo findings, PTHrP (1–36), at 100 nM,
maximally (at 20–30 min) increased NF-kB–DNA binding,
which was decreased by anti-p50 or anti-p65 antibodies, in
MCT cell nuclear extracts (Figure 8a). Moreover, this peptide
dose dependently induced p65 translocation to the nucleus in
MCT cells at 30 min, decreasing thereafter (Figure 9a and b).
Furthermore, PTHrP (1–36), within the same concentration
range and time frame, induced MCP-1 and RANTES gene
expression in these cells, an effect abolished by PTHrP (7–34)
(Figure 10a and b). Pretreatment with several NF-kB
inhibitors, which prevent IkB degradation,28,29 dramatically
inhibited the effect elicited by PTHrP (1–36) on the gene
expression of various proinflammatory factors in these cells
(Figure 11). NF-kB activation can occur associated with ERK
phosphorylation in renal cells.30,31 We presently found that
ERK 1/2 was rapidly and transiently activated by PTHrP
(1–36), at 100 nM, in MCT cells (Figure 8b). Moreover, the
ERK 1/2 kinase inhibitor U0126 significantly reduced NF-kB
activation (Figures 8a and 9a) and also overexpression of the
aforementioned proinflammatory factors by PTHrP (1–36) in
these cells (Figure 11). Neither of these inhibitors signi-
ficantly affected the expression of these factors in MCT cells
(data not shown).
PTHrP (1–36) stimulates migration of mouse macrophages
Raw 264.7
The medium conditioned by PTHrP (1–36)-treated MCT
cells was found to induce Raw 264.7 cell migration (Figure
12a). This was prevented by pretreatment with either PTHrP
(7–34) or several ERK or NF-kB inhibitors (Figure 12a). The
addition of an MCP-1 antibody to the MCT cell-conditioned
medium after PTHrP (1–36) stimulation partly inhibited its
chemoattractant activity (Figure 12a). Interestingly, the addi-
tion of PTHrP (7–34) or an N-terminal PTHrP antiserum to
this medium also neutralized in part this activity (Figure
12a), suggesting that PTHrP (1–36) might directly stimulate
Raw 264.7 cell migration. In fact, it was proven to do so when
we exposed the latter cells to PTHrP (1–36) in serum-free
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Figure 3 | Changes in several proinflammatory factors in the obstructed kidney of control and PTHrP-TG mice. Protein expression
of MCP-1 (a) (representative autoradiogram of western blot analysis is shown) and gene expression of CCR2 (b) RANTES (c), ICAM-1 (d), and
IL-6 (e) (determined by real time PCR) in the kidney of both types of mice at 2–6 days after UUO or sham operation. Experimental values
are mean±s.e.m. of 4–6 animals per group at each time. *Po001 vs corresponding value in control mice. aPo0.01 vs corresponding value
in sham-operated mice. AU, arbitrary units.
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medium (Figure 12b). A high dose (200 mg ml1) of doxy-
cycline did not affect this peptide stimulation of macrophage
migration, which was 500±100 or 544±45%, in the
presence or absence of the drug, respectively, compared to
basal value (100%) (n¼ 4), supporting further our afore-
mentioned in vivo findings in doxycycline-treated mice. In
contrast, this effect of PTHrP (1–36) was abolished by both
PTHrP (7–34) and an MCP-1 antibody (Figure 12b). PTHrP
(1–36) also directly increased MCP-1 mRNA expression in
Raw 264.7 cells, and this was abrogated by PTHrP (7–34)
(Figure 12c).
DISCUSSION
In this study, PTHrP was found to be upregulated in the
obstructed mouse kidney, even in PTHrP-TG mice, further
supporting that the PTHrP transgene does not seem to affect
endogenous PTHrP gene expression in mice.26 In contrast
to previous observations in ischemic or nephrotoxic renal
injury,1,5,6,26 PTH1R was not downregulated after UUO in
mice. Interestingly, an upregulation of both PTHrP and
PTH1R was recently observed in the kidney of diabetic mice.3
The reasons for the different response of PTH1R to various
renal injuries are presently unknown.
In the obstructed mouse kidney, PTHrP upregulation was
associated with renal fibrosis and inflammation, consistent
with previous findings in another model of acute renal
injury.6 After UUO, we observed herein that the increase of
several proinflammatory factors (namely, MCP-1, RANTES,
and ICAM-1) was of greater magnitude, associated with
higher tubular injury, in PTHrP-TG mice than in control
littermates at the end of study. In this regard, a relationship
between tubular injury and renal inflammation has been
reported.8,32,33
The kidneys of PTHrP-TG mice showed no morphologic
or functional alterations in basal conditions.3,6 In this study,
the unobstructed kidney of these mice had a higher
expression of various proinflammatory mediators than that
of their control littermates, although leukocyte infiltration
was similar in both types of mice. In this regard, we recently
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Figure 5 | Effect of doxycyclin on several proinflammatory factors in the obstructed kidney of PTHrP-TG mice. Treatment with
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in PTHrP-TG mice to the corresponding levels in control mice at day 4 after UUO. Experimental values are mean±s.e.m. of 4–6 animals
per group at each time. *Po0.01 vs corresponding value in control mice; aPo0.01 vs corresponding value in sham-operated mice; bPo0.01 vs
corresponding PTHrP-TG value.
Kidney International (2008) 73, 835–847 839
D Ra´mila et al.: PTHrP and inflammation in the obstructed mouse kidney o r i g i n a l a r t i c l e
reported that PTHrP-TG mice developed higher renal hyper-
trophy and proteinuria than control mice after diabetes
induction.3 These findings suggest that constitutive PTHrP
overexpression in mice might trigger counterregulating
mechanisms, such as nitric oxide production,34,35 which
would prevent renal damage in the absence of specific kidney
insults. Confirming this hypothesis requires further studies.
In any event, current data point to PTHrP as a factor that
could accelerate an injury-dependent development of renal
inflammation and fibrosis.
Doxycycline-induced reversal of the PTHrP transgene
in the obstructed kidney of PTHrP-TG mice restored the
response of proinflammatory factors to corresponding levels
in control mice. Moreover, in the latter mice, pretreatment
with PTHrP (7–34) reversed a significant part of several
proinflammatory effects induced by UUO. This suggests a
partial efficiency of this antagonist at the dose used and/or
that PTHrP might affect inflammation through an intracrine
mechanism. However, this is unlikely, as suppression of
PTHrP upregulation by losartan was equally efficient as
the PTH1R antagonist in inhibiting inflammation in the
obstructed mouse kidney. Interestingly, losartan was less
efficient in this regard in PTHrP-TG mice, suggesting that
PTHrP might recapitulate in part the proinflammatory
actions of angiotensin II in this setting.19,23,36
NF-kB activation is known to be a key factor in the renal
inflammatory response to kidney injury.11–14,19,37 Consistent
with the observed changes in various NF-kB-dependent
factors, we found here an increased NF-kB activity associated
with PTHrP overexpression in the obstructed mouse kidney.
Furthermore, our present in vitro data show that induction of
MCP-1, RANTES, IL-6, and CCR2 expression by PTHrP
(1–36) was dependent, at least in part, on both ERK and
NF-kB activation in MCT cells. This further supports
the notion that ERK activation is an important step in the
signaling pathways leading to NF-kB-related inflamma-
tion.30,31,38 Collectively, our findings strongly suggest that
these intracellular pathways are involved in the mechanisms
whereby PTHrP can promote renal inflammation.
A novel finding of this study was that PTHrP (1–36),
apparently through the PTH1R, directly stimulated both
MCP-1 production and cell migration in macrophage Raw
264.7 cells. Such interaction between both factors was
recently suggested to occur in macrophages within human
atheroma.39
In summary, we show here the critical role of PTHrP on
the inflammatory process after kidney obstruction in mice.
Our in vitro findings indicate that this protein upregulates
several proinflammatory factors in tubuloepithelial cells
and promotes monocyte/macrophage migration. Moreover,
ERK-mediated NF-kB activation appears to be an important
mechanism whereby PTHrP triggers renal inflammation.
The use of rodent models has provided new insights into
the molecular mechanisms underlying the pathophysiology
of kidney obstruction,8 although caution should be exercised
in extending these experimental findings to humans. Consi-
dering this limitation, our present data suggest that PTHrP
might be envisioned as a new inflammation marker and a
potential therapeutic target in the obstructed kidney.
MATERIALS AND METHODS
Animal model of UUO
We used mice with or without renal PTHrP overexpression, as
reported elsewhere.26 Briefly, mice containing a human PTHrP
(1–141) cDNA under control of a tetracycline operator were bred to
mice with a construct consisting of a g-glutamyl transpeptidase
promoter fragment upstream of a tetracycline transactivator fusion
protein to generate PTHrP-TG animals. This strategy allows the
control of transgene expression.6,26 The results with PTHrP-TG mice
were compared with those obtained with control littermates (those
bearing either one of the aforementioned constructs or normal CD-1
mice).3,6 PTHrP overexpression in these mice does not induce
significant changes in normal kidney morphology or basal renal
function.3,6,26 Experimental protocols were approved by the Institu-
tional Animal Care and Use Committee at Fundacio´n Jime´nez Dı´az.
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UUO was performed under anesthesia in sex-unselected mice
(weighing 25–35 g) by ligating the left ureter of each animal with
3-0 silk—at two locations and cutting between the ligatures—
through an abdominal incision.19 On different days thereafter, mice
were killed and the obstructed and contralateral kidneys collected.
Sham-operated mice, which had their ureters manipulated but not
ligated, served as controls. A group of mice were treated with
the PTH1R antagonist [Asn10, Leu11, D-Trp12] PTHrP (7–34)
amide [PTHrP (7–34)] (35mg day1, intraperitoneally; Bachem,
Bubendorf, Switzerland), the AT1 receptor antagonist losartan
(10 mg kg1 day1, intraperitoneally; MSD, Merck Sharp & Dohme,
Spain), or the AT2 receptor antagonist PD123319 (30 mg kg
1 day1,
subcutaneously; Sigma, St Louis, MO, USA), before UUO, and
during the study period. These doses were found to be efficient to
block some PTHrP or angiotensin II effects in mice.19,27,37
Kidney portions were separated from each mouse. One of them
was fixed in 4% p-formaldehyde for histologic studies. One half of
the remaining kidney portion was used for protein analysis and the
other half for total RNA isolation, and they were stored at 20 1C
for subsequent analysis.
Histology and immunohistochemistry
Fixed renal tissue sections were dehydrated and embedded in
paraffin. Histological and immunostaining analysis were performed
on serial paraffin-embedded renal tissue sections (2 mm) within the
same mouse tissue. Renal histology was evaluated by hematoxylin/
eosin and Masson’s staining.
Immunohistochemistry was performed using a previously
described protocol,6 a rabbit polyclonal antibody to CD3 antigen
in mouse T lymphocytes (Dako, Glostrup, Denmark) (at 1:200
dilution), and a monoclonal antibody against F4/80 antigen in
murine monocytes/macrophages (Serotec, Oxford, UK).6 Some
tissue samples were incubated without the primary antibody as
negative controls. All stainings were evaluated in at least eight
different high-power fields per section in four sections from each
mouse in a total of 4–6 mice per group. The percentage of stained
area for Masson’s staining was graded by the following semiquanti-
tative score: 0, no staining; 1, up to 25%; 2, between 25 and 50%;
and 3, 450%, as reported.6,19 Tubular atrophy was graded from 0 to
3, on the basis of the presence of necrosis and brush border loss,
irregular and thin epithelium, and/or thickened tubular basement
membrane.6,19 The number of CD3- and F4/80-positive interstitial
cells was counted per field. All evaluations were performed by 2–3
independent observers in a blinded fashion, and the corresponding
mean score value was obtained for each mouse.
Cell cultures
MCT cells (70 000 cells cm2) that respond to PTHrP (1–36)6
and Raw 264.7 cells (ECACC 91062702) (3 106 cells ml1), which
have proven to be useful for studies on the mechanisms of
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inflammation,40–42 were incubated in serum-depleted medium
(RPMI 1640), with or without PTHrP (1–36), for 5 min to 3 h. In
some experiments, PTHrP (7–34) (1 mM) or several NF-kB inhibitors
(parthenolide (25mM; Sigma); carbobenzoxy-L-leucyl-L-leucyl-L-
leucynal (MG-132) (10 mM; Calbiochem, San Diego, CA, USA);
and Bay 11-7082 (25mM; Sigma), or the ERK 1/2 kinase inhibitor
U0126 (25 mM; Promega, Madison, WI, USA)) were added to cell
cultures 1 h before PTHrP (1–36).
Macrophage migration assay
Subconfluent MCT cells were exposed to different agonists for 12 h.
RAW 264.7 cells were seeded on Transwell chambers (5 mm pore size;
Corning, New York, NY, USA) (2 105 cells per insert) and exposed
to the medium conditioned by MCT cells, with or without PTHrP
(7–34), or neutralizing rabbit polyclonal antibodies to either PTHrP
(N-terminal C13 antiserum or C-terminal C6 antiserum)43,44 or
MCP-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (each at
1:100 dilution), for 24 h. To evaluate the direct effect of PTHrP
(1–36) on Raw 264.7 cell migration, the MCT cell-conditioned
medium was replaced by serum-depleted medium containing or not
containing (basal medium) PTHrP (1–36), with or without PTHrP
(7–34) or anti-MCP-1 antibody for 24 h. Preliminary experiments
showed that this time was optimal to assess changes on Raw 264.7
cell motility. Cells migrating into the lower chamber were counted
in a FACS Calibur cytometer (BD Biosciences, Franklin Lakes, NJ,
USA).
Western blot analysis
Kidney tissue or cell samples were homogenized in lysis buffer
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate,
1 mM phenylmethylsulfonylfluoride (PMSF), and 0.8mM aprotinin,
pH 7.4). Proteins (30–60 mg per lane, as determined by Bradford’s
method (Pierce, Rockford, IL, USA), using bovine serum albumin
(BSA) as standard) were separated on 10–15% polyacrylamide-
sodium dodecyl sulfate gels under reducing conditions. Samples
were then transferred onto polyvinylidene fluoride membranes
(Millipore Corporation, Bedford, MA, USA), blocked with 5%
defatted milk in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05%
Tween-20, or 5% BSA in PBS with 0.05% Tween-20 (for PTHrP),
and incubated overnight at 4 1C with the following rabbit polyclonal
antibodies to MCP-1 (1:500; Santa Cruz Biotechnology); PTH1R
(Ab-IV, 1:1000); PTHrP (C6, 1:2500);3–6,39 ERK 1/2 or phosphory-
lated ERK 1/2 (Thr202/Tyr204) (Cell Signaling Technology; Beverly,
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MA, USA) (each at 1:2000). Membranes were subsequently incu-
bated with relevant peroxidase-conjugated goat anti-rabbit or anti-
mouse IgG and developed by ECL chemiluminescence (Amersham,
Buckinghamshire, UK). Densitometric values of fluorogram bands
were normalized to those of b-actin or a-tubuline.
Real-time PCR
Cell total RNA was isolated with Trizol (Invitrogen, Groningen,
The Netherlands), and gene expression was analyzed by real-time PCR
using a described protocol and an ABI PRISM 7500 system (Applied
Biosystems, Foster City, CA, USA).19 Unlabeled mouse-specific primers
for PTHrP (Mm00436057_m1); PTH1R (Mm00441046_m1);
MCP-1 (Mm00441242_m1); RANTES (Mm01302428_m1); IL-6
(Mm00446190_m1); ICAM-1 (Mm00516023_m1); and CCR2
(Mm99999051_gH) and TaqMan MGB probes were obtained by
Assay-by-DesignSM (Applied Biosystems). The mRNA copy numbers
were calculated for each sample using the copy threshold value and
normalized against 18S rRNA, as reported.19
Determination of NF-jB activity
NF-kB activity in renal and MCT cell extracts was assayed as
described previously.19,28 Briefly, ground-frozen kidney pieces were
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resuspended in 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid), pH 7.6, 20% glycerol, 350 mM NaCl, 5 mM
MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, and 0.5 mM PMSF. After
centrifugation at 40 000 g for 30 min at 4 1C, the supernatant was
collected. MCT cells were lysed with 0.1% Triton in PBS. After
centrifugation at 3000 g for 10 min, the pellet was resuspended in
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20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA
(ethylene glycol bis(b-aminoethylether)-N,N,N0,N0,-tetraacetic acid),
0.2 mM phenylmethylsulphonylfluoride (PMSF), and 1.4mM aprotinin
(nuclear extract). Tissue extracts (80mg protein) and nuclear extracts
(4mg protein) were incubated with a 32P-labeled NF-kB consensus
oligonucleotide (50-AGTTGAGGGGACTTTCCCAGGC-30; Promega).
Protein–DNA complexes were resolved on native 5% polyacrilamide/
0.25TBE gels, and dried gels were exposed to radiosensitive
film.19,28 As specificity controls, some tissue and cell extracts were
pre-incubated with a 100-fold excess of unlabeled NF-kB oligo-
nucleotide. To characterize the NF-kB–DNA complex, nuclear extracts
were pre-incubated for 2 h at 4 1C with 2ml of anti-p50 or anti-p65
antibodies (Santa Cruz Biotechnology).28
To assess changes in p65 localization, subconfluent MCT cells on
coverslips in multiwell plates were stimulated with PTHrP (1–36)
(100 nM), with or without U0126 (25mM), for 15–45 min. Cells were
fixed with 64% isopropanol/15% polyoxyethylene (Cell-fixx;
Shandon, Pittsburgh, PA, USA) and permeabilized with 0.2% Triton
X-100 in PBS for 10 min. After blocking with 3% BSA for 30 min,
cells were incubated with anti-p65 antibody (1:50; Santa Cruz
Biotechnology) for 1 h, and then with fluorescein isothiocyanate-
conjugated anti-rabbit IgG antibody (1:200; Sigma). Samples
were counterstained with propidium iodide to detect cell nuclei.
Immunofluorescence analysis was performed with a Leica DM-IRB
confocal microscope.
Statistical analysis
Results are expressed as mean±s.e.m. The effect of UUO on
different factors in vivo and both time course and dose–response of
PTHrP (1–36) treatment in vitro were evaluated by analysis of
variance followed by Dunnett’s test. Mann–Whitney test was
performed to analyze the differences between PTHrP-TG mice and
their control littermates and the effect of different antagonists
in vivo, as well as the effects of the different inhibitors in vitro.
Po0.05 was considered significant.
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